NUT 中线癌作为原发性肺肿瘤，采用安罗替尼联合姑息性放疗治疗：一例报告。
NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report.
机构信息
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Department of Pathology, The Southwest Hospital, the Southwest Hospital of Army Medical University, Chongqing, 400038, China.
出版信息
Diagn Pathol. 2022 Jan 7;17(1):4. doi: 10.1186/s13000-021-01188-y.
BACKGROUND
NUT (nuclear protein in testis) midline carcinoma (NMC) is a rapidly progressive tumor arising from midline structures. Recent cases have reported that the poor prognosis with a median survival of 6.7 months and a 2 years overall survival of 19% due to limited treatment. Based on the effect of arotinib on inhibiting tumor growth and angiogenesis. We present one patient case treated with anlotinib and radiotherapy.
CASE PRESENTATION
Here, we describe a 33-year old patient who complained of cough and chest pain and was diagnosed as a pulmonary NMC through CT scan, FISH and immunohistochemistry. In addition, we initially demonstrated that anlotinib combined with palliative radiotherapy could significantly prevent the tumor growth in a pulmonary NMC.
CONCLUSION
The report indicated that anlotinib combined with palliative radiotherapy could inhibit the tumor progression in a pulmonary NMC, which may provide a combined therapy to pulmonary NMC in the future.
背景
睾丸核蛋白中线癌（NMC）是一种从中线结构发生的快速进展性肿瘤。最近的病例报告显示，由于治疗手段有限，中位生存期为 6.7 个月，总生存期为 2 年，预后较差，仅为 19%。基于阿来替尼抑制肿瘤生长和血管生成的作用。我们报告了一例接受阿来替尼和放疗治疗的患者病例。
病例介绍
这里，我们描述了一位 33 岁的患者，他因咳嗽和胸痛就诊，通过 CT 扫描、FISH 和免疫组织化学检查被诊断为肺 NMC。此外，我们最初证明阿来替尼联合姑息性放疗可显著抑制肺 NMC 中的肿瘤生长。
结论
该报告表明，阿来替尼联合姑息性放疗可抑制肺 NMC 中的肿瘤进展，这可能为肺 NMC 的未来提供一种联合治疗方法。
Zotero 插件